Loading...
By Kristin J. Kelley
Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH
The FDA has approved evolocumab (Repatha) to lower LDL cholesterol in adults with heterozygous familial hypercholesterolemia, homozygous familial hypercholesterolemia, or clinical atherosclerotic cardiovascular disease and for whom current therapy options aren't sufficient.
The injectable drug — which should be used as an adjunct to diet and maximally tolerated statin therapy — is the second drug the agency has approved in as many months that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 inhibition ultimately helps liver receptors remove LDL cholesterol from the blood.
Evolocumab's safety and efficacy were evaluated in nine placebo-controlled studies. Reductions in LDL favored the drug, including a 60% reduction relative to placebo in one trial. Side effects included back pain, flu, nasopharyngitis, and injection-site reactions. Allergic reactions (hives, rash) have also occurred.
Studies are ongoing to evaluate the drug's effects on cardiovascular outcomes.
The New York Times notes that with evolocumab priced at $14,100 per year, PCSK9 inhibitors could add "billions of dollars to the nation's medical bill."
Comment
LINK(S):
FDA news release (Free)
New York Times coverage of evolocumab approval (Free)
New York Times "Mending Hearts" story (Free)
Background: Physician's First Watch coverage of first PCSK9 inhibitor (alirocumab) approval (Free)